ICH E2B Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports

Target entity: ICH E2B Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports
Context triple: [ICH E2D, relatedTo, ICH E2B Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports]

• A. ICH Harmonised Tripartite Guideline E2D Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting
  ICH E2D is an international regulatory guideline that standardizes how post-approval drug safety data are defined, managed, and rapidly reported to health authorities to ensure ongoing monitoring of medicinal product safety.
• B. ICH E2A Clinical Safety Data Management
  ICH E2A Clinical Safety Data Management is an international guideline that standardizes the collection, reporting, and evaluation of clinical safety data in drug development to support consistent pharmacovigilance and regulatory decision-making.
• C. Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs
  Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs (ICH E2C) is an international guideline that standardizes the format, content, and timing of periodic safety reports submitted by marketing authorization holders to monitor and communicate the ongoing safety profile of approved medicines.
• D. International Council for Harmonisation guideline E2C
  International Council for Harmonisation guideline E2C is a regulatory framework that provides standardized requirements for the ongoing safety evaluation and periodic benefit-risk assessment of marketed medicinal products.
• E. Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
  The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Target entity: ICH E2B Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports
Target entity description: ICH E2B Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports is an international guideline that standardizes the format and content of electronic individual case safety reports to support consistent global pharmacovigilance and regulatory reporting.

• A. ICH Harmonised Tripartite Guideline E2D Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting
  ICH E2D is an international regulatory guideline that standardizes how post-approval drug safety data are defined, managed, and rapidly reported to health authorities to ensure ongoing monitoring of medicinal product safety.
• B. ICH E2A Clinical Safety Data Management
  ICH E2A Clinical Safety Data Management is an international guideline that standardizes the collection, reporting, and evaluation of clinical safety data in drug development to support consistent pharmacovigilance and regulatory decision-making.
• C. Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs
  Clinical Safety Data Management: Periodic Safety Update Reports for Marketed Drugs (ICH E2C) is an international guideline that standardizes the format, content, and timing of periodic safety reports submitted by marketing authorization holders to monitor and communicate the ongoing safety profile of approved medicines.
• D. International Council for Harmonisation guideline E2C
  International Council for Harmonisation guideline E2C is a regulatory framework that provides standardized requirements for the ongoing safety evaluation and periodic benefit-risk assessment of marketed medicinal products.
• E. Pharmacovigilance Risk Assessment Committee within the European Medicines Agency
  The Pharmacovigilance Risk Assessment Committee within the European Medicines Agency is an expert body responsible for evaluating and monitoring the safety of medicines across the European Union and providing recommendations on managing and communicating medicine-related risks.
• F. None of above. chosen